TIDMNSCI
RNS Number : 8681B
NetScientific PLC
15 June 2021
NetScientific plc
("NetScientific", the "Group" or the "Company")
PDS Biotech Announces Proposed Offering of Common Stock
London, UK - 15 June 2021 - NetScientific plc (AIM: NSCI), the
international life sciences and sustainability technology
investment and commercialisation Group, announces that its
portfolio company, PDS Biotechnology Corporation (Nasdaq: PDSB),
has announced that it has commenced an underwritten public offering
of shares of its common stock
The full text of the announcement from PDS Biotechnology is
reproduced below and is available online here:
https://www.pdsbiotech.com/investors/news-center/press-releases/press-releases1/113-2021-news/536-iotechnnouncesroposedfferingofommontock20210614
###
FLORHAM PARK, N.J., June 14, 2021 (GLOBE NEWSWIRE) -- PDS
Biotechnology Corporation (Nasdaq: PDSB) ("PDS Biotech" or the
"Company"), a clinical-stage immunotherapy company developing novel
cancer therapies based on the Company's proprietary Versamune(R)
T-cell activating technology, today announced that it has commenced
an underwritten public offering of shares of its common stock. All
of the shares of common stock to be sold in the offering will be
offered by PDS Biotech. PDS Biotech intends to grant the
underwriters a 30-day option to purchase up to an additional 15% of
the shares of common stock offered in the public offering. The
offering is subject to market conditions, and there can be no
assurance as to whether or when the offering may be completed, or
as to the actual size or terms of the offering.
Cantor Fitzgerald & Co. is acting as sole bookrunner for the
offering.
PDS Biotech intends to use a portion of the net proceeds from
this offering for the development of our clinical pipeline and for
general corporate purposes including working capital.
A shelf registration statement on Form S-3 relating to the
public offering of the shares of common stock described above was
filed with the Securities and Exchange Commission (the "SEC") and
became effective on July 31, 2020. A preliminary prospectus
supplement relating to the offering has been filed with the SEC.
Copies of the preliminary prospectus supplement and accompanying
prospectus may be obtained from Cantor Fitzgerald & Co., 499
Park Avenue, 4th Floor, New York, NY 10022, Attn: Capital Markets
Department, or by email at prospectus@cantor.com .
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy these securities, nor shall there
be any sale of these securities in any state or other jurisdiction
in which such offer, solicitation or sale would be unlawful prior
to the registration or qualification under the securities laws of
any such state or other jurisdiction.
About PDS Biotechnology
PDS Biotech is a clinical-stage immunotherapy company developing
a growing pipeline of cancer immunotherapies based on the Company's
proprietary Versamune(R) T-cell activating technology platform. Our
Versamune(R) -based products overcome the limitations of current
immunotherapy by inducing in vivo, large quantities of
high-quality, highly potent polyfunctional tumor specific CD4+
helper and CD8+ killer T-cells. PDS Biotech has developed multiple
therapies, based on combinations of Versamune(R) and
disease-specific antigens, designed to train the immune system to
better recognize diseased cells and effectively attack and destroy
them. Our immuno-oncology product candidates are initially being
studied in combination therapy to potentially enhance efficacy
without compounding toxicity across a range of cancer types. The
Company's lead investigational cancer immunotherapy product PDS0101
is currently in Phase 2 clinical studies in HPV-associated cancers.
The Company's pipeline products address various cancers including
breast, colon, lung, prostate and ovarian cancers.
Forward Looking Statements
This communication contains forward-looking statements
(including within the meaning of Section 21E of the United States
Securities Exchange Act of 1934, as amended, and Section 27A of the
United States Securities Act of 1933, as amended) concerning PDS
Biotech and other matters. These statements may discuss goals,
intentions and expectations as to future plans, trends, events,
results of operations or financial condition, or otherwise, based
on current beliefs of the Company's management, as well as
assumptions made by, and information currently available to,
management. Forward-looking statements generally include statements
that are predictive in nature and depend upon or refer to future
events or conditions, and include words such as "may," "will,"
"should," "would," "expect," "anticipate," "plan," "likely,"
"believe," "estimate," "project," "intend," "forecast," "guidance",
"outlook" and other similar expressions among others.
Forward-looking statements are based on current beliefs and
assumptions that are subject to risks and uncertainties and are not
guarantees of future performance. Actual results could differ
materially from those contained in any forward-looking statement as
a result of various factors, including, without limitation: the
Company's ability to complete the contemplated offering; the
Company's anticipated capital requirements; and other factors,
including legislative, regulatory, political and economic
developments not within the Company's control, including unforeseen
circumstances or other disruptions to normal business operations
arising from or related to COVID-19. The foregoing review of
important factors that could cause actual events to differ from
expectations should not be construed as exhaustive and should be
read in conjunction with statements that are included herein and
elsewhere, including the risk factors included in the Company's
annual and periodic reports filed with the SEC. The forward-looking
statements are made only as of the date of this press release and,
except as required by applicable law, the Company undertakes no
obligation to revise or update any forward-looking statement, or to
make any other forward-looking statements, whether as a result of
new information, future events or otherwise.
###
Further details and the information required in accordance with
the requirements of Article 19(3) of the EU Market Abuse Regulation
No 596/2014 are set out at the end of this announcement.
For more information, please contact:
NetScientific Via Walbrook PR
Ilian Iliev, CEO
WH Ireland (NOMAD, Financial Adviser
and Broker)
Chris Fielding / Darshan Patel +44 (0)20 7220 1666
Walbrook PR +44 (0)20 7933 8780 or netscientific@walbrookpr.com
Nick Rome / Nicholas Johnson / Paul 07748 325 236 / 07884 664 686 / 07980
McManus 541 893
About NetScientific
NetScientific plc (AIM: NSCI) is a holding company, that invests
in, develops, commercialises and realises shareholder value in life
sciences/healthcare, sustainability and technology companies, which
offer significant growth potential predominately in the UK and USA,
as well as globally.
With the acquisition of EMV Capital in August 2020, the Group
doubled its portfolio from 8 to 17 companies, either through direct
subsidiary, balance sheet investment or capital under advisory,
varying from start-up private companies to publicly listed
equities.
NetScientific delivers shareholder returns through a proactive
and hands-on management approach to their portfolio companies;
identifying, investing in, and helping to build game-changing
companies. The Group targets value inflection points and the
release of value through partial or full exits from trade sales,
public listings, or equity sales. The Company has a strong
transatlantic and growing international presence, providing
attractive expansion prospects.
NSCI can deploy a capital-light investment structure; utilising
the power of the PLC Brand, and the NetScientific balance sheet to
anchor future investments and achieve a multiplier effect by
attracting 3rd party investment for the portfolio companies.
NetScientific is headquartered in London, United Kingdom, and
was admitted to trading on AIM, a market operated by the London
Stock Exchange, in 2013 (website: netscientific.net ).
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
MSCFFFELRVISLIL
(END) Dow Jones Newswires
June 15, 2021 02:00 ET (06:00 GMT)
Netscientific (LSE:NSCI)
Gráfico Histórico do Ativo
De Jun 2024 até Jul 2024
Netscientific (LSE:NSCI)
Gráfico Histórico do Ativo
De Jul 2023 até Jul 2024